Close Menu

non-small cell lung cancer

Using gene expression data on nearly 800 non-small lung cancer samples from four previously published studies, a team of Duke University researchers has identified age- and sex-specific pathways linked to NSCLC recurrence risk.

Rosetta plans to use the proceeds for general corporate purposes and to support the development of its microRNA-based diagnostic pipeline.

The microRNA-based molecular diagnostics developer plans to use earnings from the sale of securities for a range of corporate purposes.

A new study from Johns Hopkins and Rosetta researchers finds the miRview NSCLC test to be effective.

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

Biodesix offers to help pay for the cost of the test for those patients whose doctors have determined they need it, but who don't have adequate insurance coverage.

The proceeds will support commercialization of the company's gene expression-based assay for early-stage non-small-cell lung cancer.

The two companies announced plans to develop a companion diagnostic to predict whether non-squamous non-small cell lung cancer patients can benefit from combination treatment with Alimta and cisplatin based on the thymidylate synthase biomarker.

Almac and Lilly will study a predictive marker for use as a companion diagnostic for a combination therapy.

According to an editorial in the New England Journal of Medicine, two new studies suggest "that EGFR mutations represent favorable prognostic markers of survival and are predictive of tumor shrinkage, but the evidence that they can predict a differential effect of tyrosine kinase inhibitors on survival is incomplete."

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.